reddy's analysis, page-31

Thanks Lightsup, meanwhile Arixtra continues to expand, sorry haven't signed up for the full article as yet:

Arixtra filed for acute treatment uses in Japan
07 April 2010
Ian Haydock
GlaxoSmithKline has made a regulatory submission in Japan for the approval of Arixtra (fondaparinux sodium) for the additional indications of treatment of acute pulmonary thromboembolism and acute deep vein thrombosis (DVT).

http://www.scripnews.com/researchdevelopment/Arixtra-filed-for-acute-treatment-uses-in-Japan-239304